Annual report pursuant to Section 13 and 15(d)

Acquisition of Aquarius Biotechnologies, Inc. (now Matinas Biopharma Nanotechnologies, Inc.) (Details Narrative)

v3.8.0.1
Acquisition of Aquarius Biotechnologies, Inc. (now Matinas Biopharma Nanotechnologies, Inc.) (Details Narrative) - USD ($)
 12 Months Ended
Jan. 29, 2015
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Business Acquisition [Line Items]        
Percentage of approval shareholders 100.00%      
Business combination, recognized identifiable assets acquired, goodwill, and liabilities assumed, net, total $ 2,873,035      
Contingent consideration classified as equity, fair value disclosure       $ 753,346
Business combination, recognized identifiable assets acquired and liabilities assumed, deferred tax liabilities noncurrent   $ 800,000    
Deferred income tax benefit   (356,956)  
Deferred tax liability   1,200,000    
Deferred tax liability deduction amount   800,000    
Tax Cut and Jobs Act [Member]        
Business Acquisition [Line Items]        
Deferred income tax benefit   $ 400,000    
Aquarius Biotechnologies, Inc. [Member]        
Business Acquisition [Line Items]        
Business combination, contingent consideration, upon achieving certain future clinical milestone, number of shares issuable 5,000,000      
Business acquisition, equity interest issued or issuable, number of shares 4,608,020      
Business combination, contingent consideration, upon achieving certain future regulatory milestone, number of shares issuable 3,000,000      
Milestone consideration description (i) 1,500,000 shares issuable upon the dosing of the first patient in a phase III trial sponsored by us for a product utilizing Aquarius proprietary cochleate delivery technology and (ii) 1,500,000 shares issuable upon FDA approval of the first NDA submitted by us for a product utilizing Aquarius proprietary cochleate delivery technology. The Company concluded that the contingent share issuance represented equity settled contingent consideration and have recorded the amounts to equity since inception. None of these milestones have yet been reached, and accordingly, as of December 31, 2017